Indicated for: asthma; chronic obstructive pulmonary disease
Route of administration: inhalation
Substance: fluticasone + vilanterol (glucocorticoid + beta-2 adrenergic agonist)
ATC: R03AK10 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)
The combination of fluticasone and vilanterol is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fluticasone acts as a corticosteroid, reducing airway inflammation, while vilanterol is a long-acting bronchodilator that helps relax bronchial muscles and improve breathing.
The medication is administered by inhalation, usually once a day at the same time, as directed by your doctor. Regular use is essential to maintain symptom control and prevent asthma attacks or COPD exacerbations.
Side effects may include throat irritation, oral infections, headache, or palpitations. Rarely, severe allergic reactions or worsening of respiratory symptoms may occur. If you experience difficulty breathing or facial swelling, contact your doctor immediately.
The combination of fluticasone and vilanterol is effective in managing asthma and COPD, but correct use and medical monitoring are necessary to ensure the safety and effectiveness of the treatment.